Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.
Vol 86 • 2025 • Number 1
Read the Current Issue
Original Research
Psychological Support in Psychedelic Therapy
Original Research
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research
Suicidal Behaviors and Obstructive Sleep Apnea
Editorial
A Collaborative Endeavor
Brief Report
Sex Differences in PTSD among US Military Veterans
Clinical and Practical Psychopharmacology